Rabavert (Pf) (rabies vaccine, purified chicken embryo cell (PCEC)/PF)

Whenever possible, the rabies vaccine (HDCV; Imovax(R) or PCECV; RabAvert(R)) used for the initial dose should be used for subsequent doses in the vaccine series in the same individual. Although only limited data are available to date, most experts state that rabies vaccines available in the US may be considered interchangeable. The ACIP states that clinical studies are not available to date showing differences in efficacy or safety if the vaccine series is completed with a different preparation.

The recommended vaccination schedule should be adhered to as closely as possible. If a minor deviation from the schedule occurs (e.g., a dose is delayed by a few days), the dose should be given and the vaccination schedule should be resumed using the same interval between doses. If a substantial deviation from the schedule occurs, serologic testing should be performed 7-14 days after the final vaccine dose to assess immune status. For the 2-dose preexposure prophylaxis vaccine series, when substantial delays occur (2 weeks or more) from the recommended date of the second dose, local and state public health authorities should be consulted for guidance.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

The manufacturers state that rabies vaccine should be given to pregnant femalesonly if clearly needed. However, because of the potential risks of inadequately treated rabies exposure and because limited data indicate that fetal abnormalities have not been associated with rabies vaccine, the ACIP, CDC, AAP, American College of Obstetricians and Gynecologists (ACOG), and the manufacturers state that pregnancy is not considered a contraindication for postexposure prophylaxis. ACOG recommends that each pregnant female be considered individually and that public health authorities be consulted. In addition, when a substantial risk of rabies exposure is present, preexposure vaccination may be indicated during pregnancy. Animal reproduction studies have not been performed with HDCV (Imovax(R)) or PCECV (RabAvert(R)) rabies vaccine.

It is not known if antigens contained in rabies vaccine are distributed into milk. The CDC states that use of rabies vaccine in nursing femalesshould follow the same guidelines as other adults. Because inactivated vaccines do not multiply within the body, the ACIP states that they should not pose any unusual problems for nursing females or their infants.

The manufacturer of PCECV (RabAvert(R)) rabies vaccine states that nursing is not a contraindication to rabies postexposure prophylaxis because of the possible consequences of inadequately treated rabies exposure. Preexposure vaccination with the vaccine in nursing femalesmay also be indicated if the risk of rabies exposure is substantial.

No enhanced messaging available.